These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

186 related items for PubMed ID: 29574193

  • 21. A randomized phase I study comparing the pharmacokinetics of a bevacizumab (HD204) biosimilar to European Union- and United States of America-sourced bevacizumab.
    Demarchi M, Coliat P, Barthelemy P, Schott R, BenAbdelghani M, Kim M, Hii JCS, Feyaerts P, Ang FRX, Derde MP, Deforce F, Petit T, Schwabe C, Wynne C, Park LS, Pivot X.
    PLoS One; 2021; 16(9):e0248222. PubMed ID: 34555031
    [Abstract] [Full Text] [Related]

  • 22. Charge Variants of an Avastin Biosimilar Isolation, Characterization, In Vitro Properties and Pharmacokinetics in Rat.
    Zhao YY, Wang N, Liu WH, Tao WJ, Liu LL, Shen ZD.
    PLoS One; 2016; 11(3):e0151874. PubMed ID: 26987122
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Analytical Similarity of a Proposed Biosimilar BVZ-BC to Bevacizumab.
    Yu C, Zhang F, Xu G, Wu G, Wang W, Liu C, Fu Z, Li M, Guo S, Yu X, Wang L.
    Anal Chem; 2020 Feb 18; 92(4):3161-3170. PubMed ID: 31983199
    [Abstract] [Full Text] [Related]

  • 27. Bevacizumab biosimilars: scientific justification for extrapolation of indications.
    Melosky B, Reardon DA, Nixon AB, Subramanian J, Bair AH, Jacobs I.
    Future Oncol; 2018 Oct 18; 14(24):2507-2520. PubMed ID: 29690784
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. The effect of paclitaxel and nab-paclitaxel in combination with anti-angiogenic therapy in breast cancer cell lines.
    Tonissi F, Lattanzio L, Merlano MC, Infante L, Lo Nigro C, Garrone O.
    Invest New Drugs; 2015 Aug 18; 33(4):801-9. PubMed ID: 25947567
    [Abstract] [Full Text] [Related]

  • 31. Biological Pathways Involved in Tumor Angiogenesis and Bevacizumab Based Anti-Angiogenic Therapy with Special References to Ovarian Cancer.
    Loizzi V, Del Vecchio V, Gargano G, De Liso M, Kardashi A, Naglieri E, Resta L, Cicinelli E, Cormio G.
    Int J Mol Sci; 2017 Sep 14; 18(9):. PubMed ID: 28906427
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Gastrointestinal cancer cells treatment with bevacizumab activates a VEGF autoregulatory mechanism involving telomerase catalytic subunit hTERT via PI3K-AKT, HIF-1α and VEGF receptors.
    Mahfouz N, Tahtouh R, Alaaeddine N, El Hajj J, Sarkis R, Hachem R, Raad I, Hilal G.
    PLoS One; 2017 Sep 14; 12(6):e0179202. PubMed ID: 28594907
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Biological Characterization of SB3, a Trastuzumab Biosimilar, and the Influence of Changes in Reference Product Characteristics on the Similarity Assessment.
    Lee JH, Paek K, Moon JH, Ham S, Song J, Kim S.
    BioDrugs; 2019 Aug 14; 33(4):411-422. PubMed ID: 31190280
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. FDA's Approval of the First Biosimilar to Bevacizumab.
    Casak SJ, Lemery SJ, Chung J, Fuchs C, Schrieber SJ, Chow ECY, Yuan W, Rodriguez L, Gwise T, Rowzee A, Lim S, Keegan P, McKee AE, Pazdur R.
    Clin Cancer Res; 2018 Sep 15; 24(18):4365-4370. PubMed ID: 29743182
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. A randomized study comparing the pharmacokinetics of the potential biosimilar PF-06438179/GP1111 with Remicade® (infliximab) in healthy subjects (REFLECTIONS B537-01).
    Palaparthy R, Udata C, Hua SY, Yin D, Cai CH, Salts S, Rehman MI, McClellan J, Meng X.
    Expert Rev Clin Immunol; 2018 Apr 15; 14(4):329-336. PubMed ID: 29504427
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 10.